The addition of chemotherapy to Tagrisso (osimertinib) extended median progression-free survival by nearly nine months in EGFR-mutated advanced lung cancer in the FLAURA2 Phase III trial.
This combination reduced the risk of disease progression by 38% versus Tagrisso monotherapy, the current first-line global standard of care.
"With these convincing data, patients may soon have a choice of two highly effective osimertinib-based treatment options in this advanced disease setting"By investigator assessment, the combination extended median progression-free survival (PFS) by 8.8 months versus the AstraZeneca (LSE: AZN) drug alone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze